KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Pacira BioSciences (PCRX) over the last 15 years, with Q3 2025 value amounting to $0.52.

  • Pacira BioSciences' Debt to Equity rose 2587.41% to $0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.52, marking a year-over-year increase of 2587.41%. This contributed to the annual value of $0.75 for FY2024, which is 42836.37% up from last year.
  • Latest data reveals that Pacira BioSciences reported Debt to Equity of $0.52 as of Q3 2025, which was up 2587.41% from $0.4 recorded in Q2 2025.
  • Pacira BioSciences' 5-year Debt to Equity high stood at $0.94 for Q4 2021, and its period low was $0.12 during Q2 2024.
  • For the 5-year period, Pacira BioSciences' Debt to Equity averaged around $0.37, with its median value being $0.37 (2022).
  • In the last 5 years, Pacira BioSciences' Debt to Equity plummeted by 7183.99% in 2023 and then surged by 42836.37% in 2024.
  • Quarter analysis of 5 years shows Pacira BioSciences' Debt to Equity stood at $0.94 in 2021, then tumbled by 60.87% to $0.37 in 2022, then crashed by 61.26% to $0.14 in 2023, then skyrocketed by 428.36% to $0.75 in 2024, then tumbled by 31.11% to $0.52 in 2025.
  • Its Debt to Equity stands at $0.52 for Q3 2025, versus $0.4 for Q2 2025 and $0.38 for Q1 2025.